FDA's drug vote may show risk stance
An FDA panel is expected to endorse a new blood-thinning drug by Eli Lilly. The decision could have a big impact on how powerful drugs with potentially risky effects are brought to the market. Dan Grech reports.
Generic drugs (William Thomas Cain, Getty Images)
More on Health
TEXT OF STORY
Today an FDA panel is expected to recommend approval of a new blood-thinning drug by Eli Lilly. The decision could set a precedent for how powerful, but risky new drugs are brought to market. Marketplace's Dan Grech has more.
DAN GRECH: The new drug is called prasugrel. It's a competitor to Plavix, one of the world's best selling prescription drugs. Studies found prasugrel is better than Plavix at preventing heart attacks and strokes. But the new drug also can lead to fatal bleeding in some patients.
James Unland edits the Journal of Health Care Finance. He says the FDA has been criticized for being too slow to approve risky new drugs, and for not being up front about the risks.
JAMES UNLAND: This is a breath of fresh air for the FDA to target risky drugs to the proper patients and to warn both the medical community and consumers about them.
Unland says an FDA warning won't stop the drug from finding a big market.
UNLAND: There are still billions of dollars in revenue available for properly targeted drugs. This is not an all or nothing proposition.
Analysts estimate that sales of prasugrel could reach a billion dollars a year for drug maker Eli Lilly.
I'm Dan Grech for Marketplace.
Comments
Comment | Refresh
Post a Comment: Please be civil, brief and relevant.
Email addresses are never displayed, but they are required to confirm your comments. All comments are moderated. Marketplace reserves the right to edit any comments on this site and to read them on the air if they are extra-interesting. Please read the Comment Guidelines before posting.
You must be 13 or over to submit information to American Public Media. The information entered into this form will not be used to send unsolicited email and will not be sold to a third party. For more information see Terms and Conditions and Privacy Policy.